Beam Therapeutics Inc (NASDAQ:BEAM) currently has a daily average trading volume of 1.16M but it saw 1496919 shares traded in last market. With a market cap of 2.29B USD, the company’s current market price of $27.65 came falling about -0.61 while comparing to the previous closing price of $27.82. In past 52 weeks, the stock remained buoying in the range of price level as high as $49.50 and as low as $20.84. In the recent trading on the day, stock has struck highest price mark of $27.515 while lowest mark touched by it was $28.9499.
Taking a look at 20-day trading activity of Beam Therapeutics Inc (BEAM) gives us an average price of $25.63, while its current price level is -44.14% below from 52-week high level whereas it is 32.68% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $26.52 while that of 200 days or SMA-200 reads an average of $25.19. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.70% during that period while stretching the period over a month that increases to 6.75%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 57.65 which implies that the stock is in neutral territory.
Leerink Partners upgraded its recommendation for the stock as a “Outperform” from “Market Perform” on November 06, 2024 while assigning a price target range of $27-$39.
Over the week, BEAM’s stock price is moving 1.36% up while it is 4.89% when we observe its performance for the past one month. Year-to-date it is 11.49% up and over the past year, the stock is showing an upside performance of 6.63%.
The company is expected to be releasing its next quarterly report in March, for which analysts forecasted an EPS of -1.22 while estimate for next year EPS is -4.68. In next quarter, company is expected to be making quarterly sales of $15.15M as analysts are expecting the sales for current fiscal year at $51.42M and seeing the company making $58.9M in sales next year. Moreover, analysts are in estimates of $16.47M for current-quarter revenue.
Currently, Beam Therapeutics Inc’s total number of outstanding shares is 82.56M with 1.48% of that held by the insiders while 94.61% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -15.27% and return on equity (ROE) at -18.29%. Stock’s beta reads 1.91. Stock has a price to book (P/B) ratio of 2.88 while price to sale or P/S ratio amounts to 6.55. Its return on asset (ROA) is -11.67% on average.
